Clinical trial
This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam…
NCT00150800 · UCB PHARMA Inc. (US), Industry · Completed
Key facts
| NCT number | NCT00150800 |
|---|---|
| Title | This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment |
| Official title | An Open-label, Multi-center, Follow-up Trial to Evaluate Long Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy |
| Lead sponsor | UCB PHARMA Inc. (US), Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Epilepsy |
| Intervention type | Drug |
| Interventions | Brivaracetam |
| Enrollment | 668 |
| Start date | Jan 1, 2006 |
| Primary completion | Sep 1, 2017 |
| Completion | Sep 1, 2017 |
| First posted | Sep 8, 2005 |
| Last update posted | Aug 17, 2021 |
| Countries | Australia, Brazil, Canada, India, Mexico, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: